eligibility_summary
Adults with metastatic/unresectable NSCLC, HNSCC, ESCC, GAC, EAC, or GEJ adenocarcinoma, relapsed/refractory or intolerant with no suitable SOC, adequate organ function, measurable or non‑measurable disease, ECOG 0–1. Exclude: recent other cancers, ILD/pneumonitis, DLCO<50%, ≥G3 lung disease, recent high‑dose lung RT, neuropathy ≥2, uncontrolled diabetes, active CNS mets (unless treated/stable/off steroids), meningitis, prior MMAE/β6 agents, recent chemo/targeted/antibody/radiation/surgery, recent herbal meds.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests sigvotatug vedotin (SGN-B6A), an antibody-drug conjugate (targeted cytotoxic immunotherapy). Mechanism: the monoclonal antibody binds integrin beta-6 (ITGB6) on tumor cells, is internalized, and releases the payload monomethyl auristatin E (MMAE), a microtubule inhibitor, causing microtubule disruption, mitotic arrest, and tumor cell death. Target cells/pathways: integrin beta-6–expressing epithelial solid tumors (NSCLC, head and neck SCC, esophageal SCC, gastric and esophageal/GEJ adenocarcinomas), pathways include integrin beta-6–mediated cell adhesion/signaling and the microtubule cytoskeletal network via MMAE.